Vericel (VCEL) Cash from Financing Activities (2010 - 2026)
Vericel (VCEL) posted Cash from Financing Activities of $2.7 million for Q2 2026, up 190.37% sequentially from -$3.0 million in Q1 2026, and up 64.05% YoY from $1.6 million in Q2 2025.
Vericel (VCEL) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Vericel has reported Cash from Financing Activities for 17 years, with the latest figure at $2.7 million in Q2 2026.
- Quarterly Cash from Financing Activities rose 64.05% year-over-year to $2.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.9 million (down 88.87% YoY) and the FY2025 annual result came in at $7.1 million, down 62.89% from the prior year.
- Cash from Financing Activities improved to $2.7 million in Q2 2026 per VCEL's latest filing, from -$3.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $7.1 million in Q4 2024 and troughed at -$3.0 million in Q1 2026.
- A 5-year average of $1.7 million and a median of $1.2 million in 2023 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2024 and 2026: Cash from Financing Activities jumped 1886.92% in 2024, then sank 193.15% in 2026.
- Over 5 years, Cash from Financing Activities stood at $605000.0 in 2022, then jumped by 116.03% to $1.3 million in 2023, then jumped by 443.84% to $7.1 million in 2024, then sank by 85.02% to $1.1 million in 2025, then surged by 152.77% to $2.7 million in 2026.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.7 million, -$3.0 million, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 2.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.69 Mn |
| Jun 30, 2026 | 2.69 Mn |
| Mar 31, 2026 | -2.98 Mn |
| Mar 31, 2026 | -2.98 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Dec 31, 2025 | 1.07 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Jun 30, 2025 | 1.64 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Mar 31, 2025 | 3.20 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Dec 31, 2024 | 7.11 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 2.13 Mn |
| Mar 31, 2024 | 2.13 Mn |